Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

CUSIP: 98422T100

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
73,644,024
Total 13F shares
12,460,895
Share change
-3,705,477
Total reported value
$13,460,257
Price per share
$1.08
Number of holders
30
Value change
-$2,676,053
Number of buys
11
Number of sells
13

Quarterly Holders Quick Answers

What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q1 2024

As of 31 Mar 2024, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by 30 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 12,460,895 shares. The largest 10 holders included Bain Capital Life Sciences Investors, LLC, FMR LLC, TAKEDA PHARMACEUTICAL CO LTD, RiverVest Venture Management LLC, Rock Springs Capital Management LP, Atlas Venture Life Science Advisors, LLC, VANGUARD GROUP INC, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, and MORGAN STANLEY. This page lists 30 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.